Neoadjuvant Chemotherapy in Locally Advanced Cervical Carcinoma – a Role in Patients with Para-aortic Lymph Node Involvement? A 10-year Institutional Experience

医学 放射治疗 危险系数 化疗 放化疗 淋巴结 肿瘤科 外科 内科学 置信区间
作者
H.M. Green,Nicholas Counsell,Amy Ward,Mary McCormack
出处
期刊:Clinical Oncology [Elsevier BV]
卷期号:34 (7): e281-e290 被引量:8
标识
DOI:10.1016/j.clon.2021.12.005
摘要

Overall survival and progression-free survival with concomitant chemoradiotherapy for locally advanced cervical carcinoma have been described as 66% and 58%, respectively, at 5 years. Para-aortic lymph node involvement significantly increases the risk of relapse and death. The role of additional chemotherapy in these patients is as yet undefined. This aim of the present study was to determine the outcome of a cohort of para-aortic lymph node-positive patients treated with neoadjuvant chemotherapy followed by extended-field chemoradiation compared with patients treated with extended-field chemoradiation without neoadjuvant chemotherapy.We reviewed patients with International Federation of Gynaecology and Obstetrics (FIGO) 2014 stage IB1-IVA cervical carcinoma who received extended-field radiotherapy in addition to standard pelvic chemoradiotherapy with or without neoadjuvant chemotherapy, at University College London Hospital (January 2007 to January 2018). Patients in open clinical trials were excluded.Overall, 47 patients (15.8% of 298 eligible patients) with pelvic and/or para-aortic lymph node-positive cervical carcinoma received extended-field radiotherapy. Nineteen patients (40.4%) had both neoadjuvant chemotherapy (all received six cycles) and extended-field radiotherapy (median 44 days); 28 (59.6%) patients received extended-field radiotherapy alone (median 43 days). All patients completed radical radiotherapy within 49 days. We observed evidence that patients receiving neoadjuvant chemotherapy and extended-field radiotherapy had a lower risk of death (median follow-up 4.8 years, three deaths) compared with extended-field radiotherapy alone (median follow-up 3.0 years, 11 deaths; hazard ratio = 0.27, 95% confidence interval 0.08-1.00; P = 0.05). Three-year overall survival rates were 83.3% (95% confidence interval 66.1-100) and 64.6% (95% confidence interval 44.6-84.6), respectively. A PFS benefit was seen (hazard ratio 0.25, 95% confidence interval 0.08-0.77; P = 0.02), with 3-year PFS rates of 77.8% (95% confidence interval 58.6-97.0) and 35.0% (95% confidence interval 14.0-56.0), respectively.Our institutional experience suggests that the use of additional systemic therapy before chemoradiotherapy benefits patients with locoregionally advanced (FIGO 2018 IIIC2) cervical cancer. Neoadjuvant chemotherapy was associated with longer overall survival and PFS, without compromising definitive extended-field chemoradiation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
852的应助被靓丽的含卉采纳,获得10
2秒前
田园发布了新的文献求助10
2秒前
Banbanyou发布了新的文献求助10
2秒前
桐桐的应助被怡宝采纳,获得10
4秒前
5秒前
水煮电吹风的应助被纯真忆安采纳,获得10
5秒前
多少发布了新的文献求助10
5秒前
6秒前
正直惜文发布了新的文献求助10
6秒前
标致如霜的应助被朱雀采纳,获得10
7秒前
8秒前
8秒前
詹詹发布了新的文献求助10
8秒前
Lost_Flight发布了新的文献求助10
9秒前
循河逐星发布了新的文献求助10
9秒前
10秒前
10秒前
英姑的应助被科研通管家采纳,获得10
10秒前
打打的应助被科研通管家采纳,获得10
10秒前
10秒前
Ava的应助被科研通管家采纳,获得10
11秒前
Hello的应助被科研通管家采纳,获得30
11秒前
Hello的应助被科研通管家采纳,获得10
11秒前
小蘑菇的应助被科研通管家采纳,获得10
11秒前
斯文败类的应助被科研通管家采纳,获得10
11秒前
Maestro_S的应助被科研通管家采纳,获得10
11秒前
11秒前
11秒前
稳重续的应助被科研通管家采纳,获得10
11秒前
丘比特的应助被科研通管家采纳,获得10
12秒前
田様的应助被科研通管家采纳,获得10
12秒前
liu完成签到,获得积分10
12秒前
Ava的应助被风吹麦浪采纳,获得10
13秒前
董帅铭完成签到,获得积分10
13秒前
14秒前
14秒前
15秒前
liu发布了新的文献求助10
15秒前
琳琳琳发布了新的文献求助10
17秒前
Robin发布了新的文献求助10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189615
求助须知:如何正确求助?哪些是违规求助? 9576892
关于积分的说明 21850083
捐赠科研通 7787512
什么是DOI,文献DOI怎么找? 3435723
关于科研通互助平台的介绍 2559813
邀请新用户注册赠送积分活动 2482616